Mohit Bansal
Stock Analyst at Wells Fargo
(4.31)
# 425
Out of 4,711 analysts
144
Total ratings
58.82%
Success rate
13.67%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Overweight | $30 | $17.87 | +67.88% | 1 | Dec 11, 2024 | |
| BNTX BioNTech SE | Initiates: Overweight | $170 | $113.08 | +50.34% | 1 | Dec 11, 2024 | |
| VERA Vera Therapeutics | Initiates: Overweight | $70 | $42.60 | +64.32% | 1 | Nov 21, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $100 → $105 | $92.57 | +13.43% | 9 | Nov 7, 2024 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $125 → $110 | $98.05 | +12.19% | 10 | Nov 1, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,050 | $701.85 | +49.60% | 15 | Oct 22, 2024 | |
| TVTX Travere Therapeutics | Upgrades: Overweight | $9 → $27 | $17.18 | +57.16% | 4 | Oct 21, 2024 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $58 → $62 | $46.96 | +32.03% | 5 | Oct 7, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $90 | $65.66 | +37.07% | 5 | Sep 17, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $14 → $12 | $4.45 | +169.66% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $875 → $1,000 | $767.76 | +30.25% | 15 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $320 → $335 | $263.38 | +27.19% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $240 → $225 | $146.47 | +53.62% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $120 | $122.97 | -2.42% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $26.36 | +13.81% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $205 | $175.58 | +16.76% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $540 → $555 | $397.27 | +39.70% | 8 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $135.42 | +25.54% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $52 | $57.33 | -9.30% | 7 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $12.34 | +118.80% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $38.63 | +29.43% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $19.34 | +9,594.93% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $15.52 | +93.30% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.15 | +3,030.43% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $21.21 | -10.42% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.60 | +726.58% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $2.59 | +2,216.60% | 4 | Dec 3, 2019 |
Summit Therapeutics
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $17.87
Upside: +67.88%
BioNTech SE
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $113.08
Upside: +50.34%
Vera Therapeutics
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $42.60
Upside: +64.32%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $100 → $105
Current: $92.57
Upside: +13.43%
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $98.05
Upside: +12.19%
Regeneron Pharmaceuticals
Oct 22, 2024
Maintains: Overweight
Price Target: $1,200 → $1,050
Current: $701.85
Upside: +49.60%
Travere Therapeutics
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $17.18
Upside: +57.16%
Halozyme Therapeutics
Oct 7, 2024
Downgrades: Equal-Weight
Price Target: $58 → $62
Current: $46.96
Upside: +32.03%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $65.66
Upside: +37.07%
Ironwood Pharmaceuticals
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $4.45
Upside: +169.66%
Aug 9, 2024
Maintains: Overweight
Price Target: $875 → $1,000
Current: $767.76
Upside: +30.25%
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $320 → $335
Current: $263.38
Upside: +27.19%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $146.47
Upside: +53.62%
Aug 1, 2024
Maintains: Equal-Weight
Price Target: $140 → $120
Current: $122.97
Upside: -2.42%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $26.36
Upside: +13.81%
Jul 26, 2024
Maintains: Overweight
Price Target: $200 → $205
Current: $175.58
Upside: +16.76%
Jun 24, 2024
Maintains: Overweight
Price Target: $540 → $555
Current: $397.27
Upside: +39.70%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $135.42
Upside: +25.54%
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $57.33
Upside: -9.30%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $12.34
Upside: +118.80%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $38.63
Upside: +29.43%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $19.34
Upside: +9,594.93%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $15.52
Upside: +93.30%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.15
Upside: +3,030.43%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $21.21
Upside: -10.42%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.60
Upside: +726.58%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $2.59
Upside: +2,216.60%